Short-Term Debt to Equity Ratio: Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) is a reputable biopharmaceutical player developing effective therapies for orphan diseases of the nervous system. This daily price chart reflects the dynamics of an asset with a value of 0.08. Demand for unique medications is rising due to an expanding list of diagnoses. The brand's financial stability is based on payments from insurance companies and government funds supporting individuals with narcolepsy and cataplexy.
Financial and market metric breakdowns for harmonybiosciences.com (HRMY)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Harmony Biosciences|HRMY - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Harmony Biosciences Holdings, Inc.|HRMY - Company Aggregate Debts|Debt to Book Capitalization Ratio Harmony Biosciences Inc|HRMY - Company Long-Term Loans and Borrowings|Company Short-Term Debt Harmony Biosciences|Quick Liquidity harmonybiosciences.com
- company profitability and valuation multiples indicators:
Comprehensive company analysis:HRMY Harmony Pharma
This indicator assesses the company's dependence on short-term liabilities relative to its equity, allowing for the determination of liquidity risk or the degree of aggressive expansion. A stable short-term debt-to-equity ratio confirms the ability of Harmony Biosciences (HRMY) to fund its premium elite pharmacologist fund using internal resources, which minimizes credit shocks and strengthens the fundamental resilience of the business.
Direct competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|DNLI: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital BHVN|Short-Term Debt to Capital Amylyx Pharmaceuticals Inc (AMLX)|Short-Term Debt to Equity Trevi Pharma TRVI|Ratio of Short-Term Indebtedness to Capital PRAX|AVXL - Short-Term Debt to Equity|ceribell.com (CBLL) - Short-Term Debt to Equity Ratio|Prothena Corp (PRTA) - Short-Term Debt to Equity|Current Liabilities to Capital Alector (ALEC)|Short-Term Debt to Equity Annexon Inc.|Short-Term Debt to Capital Ratio OMER (Omeros Corp.)|Short-Term Debt to Equity Ratio NGNE (Neurogene Inc.)|ACIU - Current Liabilities to Capital|Voyager Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital NMRA|Scilex Holding Co. - Short-Term Debt to Capital|TVGN: Short-Term Debt to Equity|ACOG: Short-Term Debt to Capital|CGTX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Inhibikase Therapeutics, Inc.|Current Liabilities to Capital Cassava Sciences Inc SAVA|Short-Term Debt to Equity Assertio Holdings, Inc. (ASRT)|Short-Term Debt to Capital Coefficient coyatherapeutics.com|Short-Term Debt to Capital VTGN (Vistagen)|OVID - Short-Term Debt to Equity Ratio|Acumen Pharmaceuticals, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient CervoMed, Inc. CRVO|ATHE: Short-Term Debt to Capital|Current Liabilities to Capital Clene (CLNN)|Short-Term Debt to Equity PepGen Inc|Short-Term Debt to Capital Ratio JUNS (jupiterneurosciences.com)|Short-Term Debt to Capital RLMD|Short-Term Debt to Equity Ratio Annovis Bio Inc ANVS|Short-Term Debt to Capital GRCE (Grace Therapeutics)|Firefly Neuro (AIFF) - Current Liabilities to Capital|KLTO - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient NeuroSense Therapeutics NRSN|RVPH: Short-Term Debt to Capital|MetaVia - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NeurAxis, Inc|HSDT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|Short-Term Debt to Equity Ratio bionomics.com.au NEUP|Minerva Neurosciences, Inc. - Short-Term Debt to Equity Ratio|Athira Pharma Inc (ATHA) - Current Liabilities to Capital|ADXN - Short-Term Debt to Equity|ALZN (Alzamend Neuro, Inc.) - Short-Term Debt to Capital Ratio|CYCN: Short-Term Debt to Capital|Current Liabilities to Capital Protagenic Therapeutics, Inc. (PTIX)|Short-Term Debt to Equity Ratio KTTA|Short-Term Debt to Capital Cortigent Medical|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BCLI (BrainStorm Cell Therapeutics Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|chromocell.com (CHRO) - Current Liabilities to Capital|Eliem - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital ITCI (Intra-Cellular Therapies)|LBPH: Short-Term Debt to Capital|Marinus Pharma (MRNS) - Short-Term Debt to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|NRBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Sage Therapeutics (SAGE)|Short-Term Debt to Equity Ratio Synaptogenix Inc. SNPX|Short-Term Debt to Equity Trevena, Inc TRVN|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|WENA - Short-Term Debt to Equity|CERE (cerevel.com) - Short-Term Debt to Capital Ratio